# Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: BDTX
Company: Black Diamond Therapeutics
Source: Black Diamond Therapeutics
Published: 2026-05-07 11:30 EST
Original Source URL: https://investors.blackdiamondtherapeutics.com
## Summary

Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII+ GBM C ash, cash equivalents,

## Article Body
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII+ GBM C ash, cash equivalents,
## Recent Company News
- 2026-05-21 21:14 EST — [Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-positive-phase-2-results-for-silevertinib-in-frontline-nsclc-patients-with-egfr-non-classical-mutations) — Source: Black Diamond Therapeutics
- 2026-05-19 12:00 EST — [Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-for-investors-highlighting-updated-results-from-phase-2-trial-of-silevertinib-in-1l-egfrm-nsclc) — Source: Black Diamond Therapeutics
- 2026-05-07 11:30 EST — [Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Black Diamond Therapeutics
- 2026-04-21 14:40 EST — [Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting) — Source: Black Diamond Therapeutics
- 2026-03-16 20:01 EST — [Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Black Diamond Therapeutics
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)